Trials / Completed
CompletedNCT01629745
Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial
Feasibility of Minimal Residual Disease (MRD) Determination in Pediatric B-Lineage ALL Using Deep Sequencing of the Immunoglobulin Heavy Chain Locus
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 99 (estimated)
- Sponsor
- Children's Oncology Group · Network
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Testing for minimal residual disease in blood samples from patients with acute lymphoblastic leukemia may help doctors plan better treatment. PURPOSE: This research trial studies a genetic test in detecting minimal residual disease in samples from younger patients registered on COG-AALL08B1 trial.
Detailed description
OBJECTIVES: * Assess the feasibility of minimal residual disease (MRD) determination in pediatric B-lineage acute lymphoblastic leukemia (ALL) using deep sequencing of the immunoglobulin heavy chain locus. OUTLINE: Archived blood and tumor tissue samples are analyzed for MDR using deep sequencing of immunoglobulin heavy chain locus. MDR quantification results are then compared with the flow cytometry reference methods used in COG studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | gene expression analysis | |
| OTHER | flow cytometry | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2012-08-01
- Completion
- 2016-05-01
- First posted
- 2012-06-28
- Last updated
- 2016-05-19
Source: ClinicalTrials.gov record NCT01629745. Inclusion in this directory is not an endorsement.